I was hoping someone could provide me with information regarding comparisons between the FDA approved SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin. From what I've seen, there appears to be a positive correlation between the selectivity of the meds for SGLT2 over SGLT1 and the number of UTIs and yeast infections, but I can't seem to find a good source analyzing the ADRs between these drugs and overall patient satisfaction with each of these meds. Thanks in advance.